Labiotech.eu

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

No, Novartis and Roche won’t merge (yet)!

Novartis already owns 33% of Roche, but even if both companies are headquartered in the same city of Basel (Switzerland), they still have no plans to merge. Joerg Reinhardt, The Chairman of Novartis – the second biggest Pharma company worldwide by market cap (€212Bn – J&J: €231Bn), was asked about it on the Swiss TV Bilanz […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Oct 2015

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

The Hemophilia Aid Program has just touched down the first batch of treatments in its target developing countries, as part of a 10-year commitment from US Biogen (Massachusetts) and Swedish Orphan Biovitrum AB (SOBI) from Stockholm via the World Federation of Hemophilia (WFH)’s AID project. The relief effort pledges to ship over 1 billion units […]

October 13, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 13 Oct 2015

Why can’t Novartis Commit to the Israeli Biotech Scene?

Novartis, the Swiss Acquisition-Giant from Basel, has once again taken bought a small chunk of shares from the Israel biotech scene for only $15M (2.5%), instead of making a final solid purchase. The Jerusalem biotech Gamida Cell, which has a stem-cell therapies for hematological diseases (leukemia and various types of anemia), was underwhelmed a second […]

October 13, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 13 Oct 2015

The Top 15 European Biotech VCs

Biotech wouldn’t exist without Venture Capitalists. These investors bring the cash necessary to run clinical trials or conduct the scaling-up of processes, along with many years of experience. Though admittedly Europe definitely hasn’t got as much money floating around as the US, there are many major Biotech VCs in Europe … Here are 15 of […]

October 13, 2015 - 9 minutesmins - By Philip Hemme

News and Trends 12 Oct 2015

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Monellin chain B is an artificial sweetener initially mistaken for a carbohydrate. It has since been established to actually be a natural protein based sweetner which is fairly unstable. iSweetch from the University of Naples has used E. Coli to engineer a more stable version of the protein to revolutionize the artificial sweetner industry. Monellin […]

October 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Oct 2015

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Monday: Manfred Horst on MSD, Biosimilars, KEYTRUDA and Merck & Co.’s rich history Tuesday: An Insider’s experience at the iGEM Giant Boston Jamboree 2015 Wednesday: Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize! Thursday: The Future Biotech Lab Bench: My experience of the cutting edge-tech at LABVOLUTION Friday: Alzheimer’s Disease: Phase III breakthrough Tau-therapy earns […]

October 10, 2015 - 1 minutemin - By Philip Hemme

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

glycotope ocotopharm key partnership e1457433449611

News and Trends 9 Oct 2015

Key-partnership for the most well-funded Biotech in Berlin

Berlin is growing as a massive Biotech hub, in part thanks to prestigious University of Medicine here (Charité), which is flanked by other world-class institutions (Humboldt University, Technische, Free University of Berlin etc.) and a thriving start-up scene. The most well-funded Biotech here at the moment is Glycotope, a biotech which has raised over €135M […]

October 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 9 Oct 2015

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Biotech of the week: Enterome, the Leading French Microbiome Start-up

This week we’ve left the sunny Portuguese coast behind us and arrived in the ‘City of Lights’, Paris. The capital city of France is famous for the Eiffel Tower, fashion and cuisine but what you may not know it is home to Enterome Bioscience, a pioneer in personalized therapies that focus on microbiome related diseases. […]

October 9, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

No, Novartis and Roche won’t merge (yet)!

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

Why can’t Novartis Commit to the Israeli Biotech Scene?

The Top 15 European Biotech VCs

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

Key-partnership for the most well-funded Biotech in Berlin

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

Biotech of the week: Enterome, the Leading French Microbiome Start-up

Subscribe to our newsletter to get the latest biotech news!